Top Story Today
A Blood Test for 12 Deadly Cancers Just Cleared Its Biggest Hurdle
FDA staff reviewers published their assessment of Grail's Galleri multi-cancer blood test and flagged no major concerns about accuracy, safety, or study design. The stock jumped 35% in a single session. Galleri detects cancer-related DNA fragments from a simple blood draw, catching over 73% of the 12 cancers responsible for two-thirds of U.S. cancer deaths. Tomorrow's advisory committee vote is the first time the FDA has ever evaluated a multi-cancer early detection blood test, meaning whatever framework it establishes becomes the template for every competitor that follows.
Why it matters: This vote doesn't just decide Galleri's fate. It sets the regulatory precedent for the entire multi-cancer early detection screening category, a market estimated at $1.5 billion to $3.2 billion and growing. Every company from Exact Sciences to Guardant Health is watching.
Read more →The Obesity Wars
Novo Nordisk's CagriSema Beats Tirzepatide in Head-to-Head Diabetes Trial
Novo Nordisk's CagriSema delivered 12.4% weight loss versus 9.1% for Lilly's tirzepatide 5 mg in a head-to-head Phase 3 diabetes trial. A second trial showed 21% weight loss versus placebo in obesity patients. It's the first time any drug has beaten tirzepatide in a head-to-head diabetes study, giving Novo superiority data as its FDA decision approaches in late 2026.
Read more →Novo Torched 4,000 Jobs. Wall Street Still Wasn't Impressed.
Novo unveiled a sweeping strategic reset at its Capital Markets Day: five blockbuster launches by 2030, a direct-to-consumer push, and roughly 13,000 cumulative job cuts. The stock dropped 7%. Investors wanted a knockout punch against Lilly; they got a reasonable plan and a PowerPoint deck.
Read more →Viking Therapeutics Data Makes the Giants Flinch
A $3.5 billion biotech just rattled the obesity duopoly. Viking showed patients on its injectable VK2735 lost up to 19% of body weight, then maintained 97% of that loss on every-other-week dosing. In a market projected to reach $200 billion by the early 2030s, the two-player era is ending.
Read more →Roche Crashes the Obesity Party With Serious Phase II Data
Roche's enicepatide delivered 22.5% weight loss in obesity patients and normalized blood sugar in 62% of diabetes patients at the highest dose. With no plateau at 48 weeks in the obesity study and a 5.9% discontinuation rate due to adverse events, the $2.7 billion Carmot acquisition is looking increasingly like a steal.
Read more →Clinical and Regulatory
Sarepta's Black Box Warning Rewrites the Gene Therapy Playbook
Sarepta added the FDA's most severe safety label to its Duchenne gene therapy Elevidys (for fatal liver injury) and separately cut 36% of its workforce earlier this year. The non-ambulatory indication was stripped entirely. It's a sobering case study in how accelerated approval can unravel post-launch.
Read more →The ADHD Drug That Has Nothing to Do With Stimulants
Alkermes showed the first clinical evidence that an orexin agonist can improve ADHD symptoms. In a 50-patient Phase 1b trial, ALKS 7290 produced dose-dependent improvement in just 14 days with no serious side effects. If the mechanism holds in Phase 2, it would be the first genuinely new pharmacological class for ADHD in decades.
Read more →Deals, Policy, and Money
Novartis Bets $3.2 Billion You'll Never Sit for an IV Again
Novartis signed a deal worth up to $3.22 billion with South Korea's Alteogen for technology that converts IV drugs into quick subcutaneous injections. It puts a little-known Korean biotech at the center of pharma's convenience revolution.
Read more →The White House Wants Veto Power Over Science Funding
The Trump administration is reportedly drafting an executive order letting political appointees block NIH grants based on policy alignment, not scientific merit. PhRMA and BIO warned it could undermine U.S. drug discovery. For biotech startups that depend on federally funded research, the slow erosion of grant independence is a pipeline risk hiding in plain sight.
Read more →China Wants to Invent 1 in 4 of the World's New Drugs by 2030
China's new five-year pharma plan targets 25% of global first-in-class drug approvals by 2030, up from a fraction of that today. The plan also calls for five Chinese-developed drugs generating over $1 billion each in global sales. It's a formal declaration that the fast-follower era is over.
Read more →Nvidia's Favorite Drug Company Wants to Go Public
Iambic Therapeutics, backed by Nvidia, Qatar's sovereign wealth fund, and Sequoia, filed for a $100 million Nasdaq IPO. Its AI platform designs cancer drug candidates in a closed loop with robotic labs. With one drug in Phase 1 and $12.8 million in collaboration revenue for the first half of 2026, it's the purest test yet of whether public markets will fund the AI drug discovery thesis.
Read more →